Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus ISOPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus ISOPTIN.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs ISOPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal elimination half-life: 4.5-12 hours (mean 8 hours); increases with hepatic impairment or cirrhosis
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Renal (70% as metabolites, 3-5% unchanged); biliary/fecal (25%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker